Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUNDAMENTAL: Alisporivir + PEG/RBV in HCV GT1 Non-responders/Relapsers
NCT01183169Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Aug 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of alisporivir in hepatitis C (HCV) (5 arms), sponsored by Debiopharm. Primary endpoint: Complete Early Viral Response Below Limit of Quantification at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
alisporivir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01183169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183169.